Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Suxia Han, Jun-lan Wang, Xijing Guo, Chenchen He, Xia Ying, Jinlu Ma, Yuanyuan Zhang, Qian Zhao, Qing ZhuJournal of Immunology Research 2014 · DOI

TL;DR

This study identifies serum SALL4 as a novel biomarker for predicting tumor recurrence and poor survival in hepatocellular carcinoma (HCC) patients. By analyzing SALL4 levels in both tumor tissues and patient blood, researchers found that elevated serum SALL4 is significantly associated with a worse prognosis, offering a new avenue for early risk stratification and potentially guiding treatment strategies.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a major global health concern, often diagnosed at advanced stages, which limits treatment options and leads to poor survival rates. While some studies have hinted at the role of the SALL4 protein in HCC, its expression in tumor tissues has shown complex and sometimes contradictory results, and its utility as a prognostic marker has remained unclear. Crucially, there's a lack of understanding regarding the significance of serum SALL4 levels in predicting HCC outcomes, such as tumor recurrence and overall survival. This paper aims to bridge this gap by investigating whether SALL4, detectable in the blood, can serve as a reliable and accessible biomarker for predicting the prognosis of HCC patients.

Methods

The researchers employed a multi-pronged approach:

  • Immunohistochemistry (IHC): This standard technique was used to examine SALL4 protein expression directly within liver tissue samples. They analyzed tissues from HCC patients, as well as control groups including those with chronic hepatitis B virus (HBV), liver cirrhosis, and healthy individuals.
  • Enzyme-Linked Immunosorbent Assay (ELISA): This is a widely used method for quantifying specific proteins in biological fluids. ELISA was employed to measure serum SALL4 levels in a larger cohort of HCC patients and control groups.
  • Longitudinal Follow-up: A key aspect of this study was the follow-up of HCC patients with detectable serum SALL4 over a two-year period. This allowed the researchers to correlate initial SALL4 levels with clinical outcomes like tumor recurrence and survival.
  • Statistical Analysis: Standard statistical methods, including t-tests, Mann-Whitney U tests, and Kaplan-Meier analysis, were used to evaluate the significance of the findings and the relationships between SALL4 levels and various clinical parameters.

Datasets

  • Liver Tissue Samples: 38 HCC tissues, 11 chronic hepatitis B virus (HBV) tissues, 13 liver cirrhosis tissues, and 12 healthy control tissues.
  • Serum Samples: 127 HCC patient serum samples, 27 from chronic hepatitis patients, 24 from liver cirrhosis patients, and 23 from normal controls. A subset of 64 HCC patients with positive serum SALL4 were followed up.

Key Insights and Ideas

  • SALL4 is Reexpressed in HCC Tissues: While not universally present, SALL4 protein was found to be expressed in a significant portion (47.4%) of HCC tumor tissues, aligning with previous observations of its reexpression in certain cancers.
  • Serum SALL4 is Elevated in HCC Patients: The study provides strong evidence that serum SALL4 levels are significantly higher in HCC patients compared to healthy individuals and those with chronic liver disease or cirrhosis. This suggests SALL4 might be released into the bloodstream during the disease process.
  • Dynamic Changes in Serum SALL4 Post-Treatment: Interestingly, serum SALL4 levels peaked about a week after treatment (surgery or TACE) and then declined significantly within a month. This dynamic behavior could potentially reflect treatment response or tumor burden.
  • Serum SALL4 as a Prognostic Indicator: This is the most critical insight. The study demonstrates a clear correlation between high serum SALL4 levels and a poorer prognosis, characterized by increased tumor recurrence and reduced overall survival. This is a novel finding that opens up new diagnostic possibilities.

Key Results

  • Tissue Expression: 18 out of 38 (47.4%) HCC tissue samples showed positive SALL4 staining.
  • Serum Levels: Serum SALL4 levels were significantly higher in HCC patients (median 130.43 pg/mL) compared to controls (around 48-53 pg/mL) (P < 0.001).
  • Post-Treatment Dynamics: Serum SALL4 levels increased significantly one week after treatment (median 220.42 pg/mL) compared to before treatment (median 152.54 pg/mL) (P < 0.002), and then dropped to a median of 80.12 pg/mL one month after treatment.
  • Prognostic Significance: HCC patients with high serum SALL4 levels (≥130.43 pg/mL) had a significantly higher recurrence rate (65.5%) compared to those with low levels (33.3%) (P < 0.016). Similarly, high SALL4 levels were associated with shorter median survival (375 days) compared to low SALL4 levels (536 days) (P = 0.023).

Limitations and Future Work

The authors acknowledge that the patient population in their study is limited, which is a common limitation in many clinical research papers. They also note that the exact regulatory mechanisms of SALL4 and its direct target genes in normal hepatic cells remain unclear.

Future work should focus on:

  • Larger Cohort Studies: Validating these findings in larger, more diverse patient populations is crucial.
  • Mechanistic Investigations: Further research is needed to understand how SALL4 is regulated in HCC and how it directly influences tumor progression, recurrence, and survival.
  • Therapeutic Potential: Exploring SALL4 as a therapeutic target or a marker for guiding personalized treatment strategies could be a significant next step.
  • Integration with Other Biomarkers: Investigating how serum SALL4 performs in conjunction with other known HCC biomarkers might offer a more comprehensive prognostic panel.

Summary updated

Abstract

High SALL4 serum levels are a novel biomarker in the prognosis of HCC patients.
BibTeX
@article{han2014serum,
  author = {Suxia Han and Jun-lan Wang and Xijing Guo and Chenchen He and Xia Ying and Jinlu Ma and Yuanyuan Zhang and Qian Zhao and Qing Zhu},
  title = {{Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma}},
  journal = {Journal of Immunology Research},
  year = {2014},
  doi = {10.1155/2014/262385},
}
Figure